Carcinoma, Adenoid Cystic - 25 Studies Found
Recruiting |
: Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2017-03-13 :
|
Completed |
: Study of RAD001 in Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2010-05-31 : Drug: RAD001 RAD001 10 mg po daily medication |
Not yet recruiting |
: Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety : Adenocystic Carcinoma : 2016-08-25 : Drug: Chidamide Other Name: epidaza |
Not yet recruiting |
: Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck :
: Drug: Imatinib |
Completed |
: Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck : Adenoid Cystic Carcinoma : 2007-12-19 : Drug: doxorubicin and bortezomib Patients will be treated with bortezomib 1.3 mg/m2, intravenously on da |
Recruiting |
: Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy : Adenoid Cystic Carcinoma : 2010-08-30 : Drug: Cetuximab cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface |
Active, not recruiting |
: Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck :
: 2010-02-08 : Drug: Nelfinavir 1250 mg Nelfinavir twice daily Monday - Sunday |
Completed |
: Dovitinib in Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2011-08-09 : Drug: TKI258 (Dovitinib): TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off sched |
Recruiting |
: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2016-05-19 : Drug: Lenvatinib |
Completed |
: Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2012-01-17 : Drug: Dovitinib (TKI258) 500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) |